Young Lady Launches CBD-Infused Gin Inspired by Trip to India

January 8, 2020 16:00:46

Cannabidiol, or CBD, has been having a magnificent run for the past few months. The chemical is one of the over 100 cannabinoids produced by the hemp plant (cannabis with less than 0.3% THC levels), and according to users, it has potent medicinal properties. Users claim that CBD offers relief against a plethora of conditions ranging from high blood pressure and insomnia to chronic pain.

However, there’s little scientific research to back these clams. The only instance where CBD has been clinically tried is Epidiolex, a CBD-based drug that was approved by the U.S. Food and Drug Administration (FDA) to manage…


About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.